CLAIMS

1°) Pharmaceutical compositions intended for the treatment of urinary incontinence characterized in that they contain oxybutynin as active ingredient, in combination or not with a moderated estrogen, in a mixture with a pharmaceutically acceptable excipient or an inert vehicle, which is non-toxic, intended for vaginal route or rectal route.

2°) Pharmaceutical compositions according to claim 1, characterized in that oxybutynin is chosen from oxybutynin base, its addition salts with a mineral or organic acid and their epimers.

3°) Pharmaceutical compositions according to claim 1, characterized in that the moderated estrogen is chosen from the group formed by estriol, estradiol and esters, ethers and mixed ethers of estriol or estradiol.

4°) Pharmaceutical compositions according to claim 1, characterized in that they are formulated in the form of suppositories, suppositories, vaginal capsules, rectal capsules or gels.

5°) Pharmaceutical compositions according to one of the preceding claims, characterized in that they contain from 1 to 25 mg of oxybutynin or its salts.

6°) Pharmaceutical compositions according to claim 5, characterized in that they contain from 5 to 15 mg of oxybutynin hydrochloride.

7°) Pharmaceutical compositions according to one of claims 1 to 6, characterized in that they contain a dose of little resorbed moderated estrogen ranging from 0.01 to 5 mg per unit dose.

8°) Pharmaceutical compositions according to claim 7, characterized in that the moderated estrogen is estriol at a dose of 0.1 to 2 mg.

9°) Pharmaceutical compositions according to claim 7 or claim 8, characterized in that the unit dose of estriol ranges from 0.2 mg to 1 mg.

10°) Pharmaceutical compositions according to one of the preceding claims, characterized in that they also contain one or more suspension agents.

11°) Pharmaceutical compositions according to claim 10, characterized in that the suspension agent or agents are bioadhesive silicic acid derivatives and in particular the colloidal silica marketed under the trade name Aerosil®.

12°) Pharmaceutical compositions according to one of the preceding claims, characterized in that the excipient is a fatty phase formed by semisynthetic glycerides.

13°) Pharmaceutical compositions according to claim 11, characterized in that the semisynthetic glycerides are those chosen from the products called Witepsol® and the products called Suppocire®.

14°) Pharmaceutical compositions according to one of the preceding claims characterized in that the formulations also contain one or more gelling agents.

15°) Pharmaceutical compositions according to claim 14, characterized in that the gelling agent or agents are cellulose derivatives and in particular alkylated and/or hydroxyalkylated cellulose derivatives.

16°) Pharmaceutical compositions according to claim 14, in which the gelling agent is a carbomer.

17°) Pharmaceutical compositions according to claim 16, in which the gelling agent is polycarbophil in acid form or in salified form.

18°) Pharmaceutical compositions according to claim 16 or claim 17, in which the gelling agent is polycarbophil in the form of calcium salt.

19°) Pharmaceutical compositions according to one of the preceding claims, which bring about a sustained release of the active ingredients, spread over more than twenty four hours, characterized in that the excipient is a fatty material in which the oxybutynin hydrochloride is placed in suspension.

20°) Pharmaceutical compositions according to one of the preceding claims, allowing T maxs of oxybutynin to be obtained comprised between approximately two hours and approximately sixteen hours and preferably between six hours and twelve hours,

characterized in that the excipient or the vehicle is chosen so that the speed of release is as long as possible.

21°) Pharmaceutical compositions according to one of the preceding claims, in which the excipient or the vehicle is chosen so that the administration of oxybutynin takes place once, or optionally twice, per twenty four hours.